More News! 3D Bioprinting Lab Opens in Dublin & More

Try as we might, we can’t cover all the biotech news out there! This week has brought good news for the fans of bioprinting and neurostimulation devices.

  • Synergia Medical, based in Belgium, has raised €8.1M in a Series A round to fund the development of NAOS, a neurostimulation device currently being tested to treat drug-resistant epilepsy.
  • Spanish biotech PharmaMar is licensing one of its sea-derived toxic payloads to US-based Seattle Genetics, which will use it to develop antibody-drug conjugates (ADC).
  • The AMBER centre in Dublin has partnered with Johnson & Johnson to open a dedicated 3D bioprinting lab.

  • Belgian company Bone Therapeutics has completed recruitment of patients with spinal fusion to take part in a Phase IIa trial to test its cell therapy for bone regeneration.
  • Sterna biologicals has shown that its enzyme treatment for ulcerative colitis can reduce inflammation in a Phase IIa trial.
  • French Genkyotex has shown that its drug GKT831 can efficiently target prostate cancer cells in a preclinical study.

 VOJTa Herout, mato181, BlurryMe /Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.